权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Plasmonic Detection of Free-Bilirubin in Neonates

新生儿游离胆红素的等离子体检测

基本信息

批准号：
7555459
负责人：
Christopher Darren Geddes
金额：
$ 2.01万
依托单位：
UNIVERSITY OF MD BIOTECHNOLOGY INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-05-01 至 2009-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7555459
关键词：
Applications Grants Area Award Back Bilirubin Binding Biological Biological Assay Biomedical Engineering Biotechnology Blood Blood - brain barrier anatomy Calibration Chemicals Clinical Clinical Research Clinical Trials Colloids Dependence Detection Diffuse Discipline Enzyme-Linked Immunosorbent Assay Face Film Fluorescence Gestational Age Glass Gold Health Sciences Housing Human Icterus Island Journals Label Laboratories Localized Measurement Measures Metals Methods Molecular Weight Nanostructures Neonatal Neurologic Operative Surgical Procedures Peer Review Photons Plastics Polymerase Chain Reaction Polymers Premature Infant Process Publications Purpose RNA Research Research Project Grants Risk Sampling Screening procedure Serum Serum Albumin Silicon Dioxide Silver Slide Standards of Weights and Measures Surface System Technology Testing Thick Thinking Time Toxic effect Translating United States Food and Drug Administration United States National Institutes of Health Universities Week abstracting base copolymer design detector fluorophore hydrophilicity improved instrument multidisciplinary nanoparticle neonate nervous system disorder new technology novel postnatal quantum

项目摘要

Project summary/Abstract: Over the last couple of years our laboratories have developed a new fluorescence based phenomenon, which is now having profound implications in clinical biotechnology. This new technology has led to the recent publication of over 50 peer reviewed articles, one edited hard bound volume and the launch of a new peer reviewed Springer Journal, entitled Plasmonics. This new phenomenon relies on the interactions of fluorophores with metallic nanoparticles and can increase the quantum yield of fluorescing species, provide spatially localized excitation and can even substantially improve fluorophore photostability. Our new technology clearly demonstrates that these novel effects can result in up to a million-fold more photons per fluorophore, which when applied to assay sensing platforms, provides for quick and simple high sensitivity assays. In this regard, under a recently completed NIH award to the PI, we were able to develop an enhanced assay platform for RNA target detection which has the sensitivity of PCR and ELISA, but most profoundly, without any amplification steps. In this R21 proposal we have assembled a multidisciplinary team of Spectroscopists, Biostatisticians and Clinicians alike, to develop a high sensitivity assay for the detection of free unbound Bilirubin in neonatal serum, an area of intense research and high clinical importance due to its ability to cross the blood brain barrier and participate in various neurological disorders. At present, tests for free unbound bilirubin are arduous, time consuming, and no approach has to date been standardized. The Metal-Enhanced Fluorescence (MEF) free bilirubin assay described here, offers high sensitivity detection, simple operation, can be made disposable and has the potential to even be standardized in laboratories around the world. The MEF assay functions as follows: Human Serum Albumin (HSA), which binds and transports serum free and bound bilirubin respectively, is immobilized in a hydrophilic copolymer, itself immobilized onto a glass slide. When serum, containing serum albumin predominantly bound bilirubin (> 99 %) is washed across the assay surface, free bilirubin diffuses into the polymer, binds to the embedded HSA and becomes intrinsically highly fluorescent due to its locality to surface silver nanostructures. We intend to optimize and determine the sensitivity of the assay using both laboratory and clinical samples and most importantly, statistically compare our results with the "UB analyzer", one of only 3 instruments in the USA designed to measure free bilirubin.

项目摘要/摘要：在过去的几年里，我们的实验室开发了一种新的基于荧光的现象，它现在对临床生物技术有着深远的影响。这项新技术导致了最近的出版50多篇同行评议文章，一本编辑过的精装本，并推出一个新的同行回顾了斯普林格杂志，题为等离子体。这一新现象依赖于用金属纳米颗粒和荧光团可以增加荧光物种的量子产率，提供空间局域激发，甚至可以显著提高荧光团的光稳定性。我们的新产品技术清楚地表明，这些新的效应可以导致每个光子增加一百万倍。当应用于检测传感平台时，荧光团提供了快速和简单的高灵敏度化验。在这方面，在最近完成的NIH授予PI的奖项下，我们能够开发出一种增强的 RNA靶标检测的分析平台，具有PCR和ELISA的灵敏度，但最深刻的是，不需要任何扩增步骤。在这份R21提案中，我们组建了一个多学科团队，光谱学家、生物统计学家和临床医生共同开发一种高灵敏度的检测方法新生儿血清中的游离胆红素，由于其具有很高的临床重要性，是一个非常重要的研究领域。跨越血脑屏障并参与各种神经疾病的能力。目前，对游离胆红素是费时费力的，而且到目前为止还没有标准化的方法。这个这里描述的金属增强荧光(MEF)无胆红素检测方法提供了高灵敏度的检测，操作简单，可一次性使用，甚至有可能在实验室实现标准化环游世界。MEF检测的功能如下：人血清白蛋白(HSA)，它结合和分别运输血清中的游离胆红素和结合胆红素，本身固定在亲水性共聚物中固定在玻璃片上。当血清中含有血清白蛋白时，主要结合胆红素(&gt；99 %)被洗过分析表面，游离胆红素扩散到聚合物中，与嵌入的HSA结合并由于其对表面银纳米结构的局域性而变得本质上高度荧光。我们打算使用实验室和临床样本和大多数重要的是，将我们的结果与美国仅有的3种仪器之一的“UB分析仪”进行统计比较设计用来测量游离胆红素。